Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

Inclusion Criteria: * Patient is \> or = 18 years old. * Patient has Type 2 diabetes and has been treated with at least one anti hyperglycemic medication within the 12 months prior to the Screening Period. * Patient is currently receiving an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin II receptor blocker (ARB) (Renin Angiotensin System (RAS) inhibitor). * For entry in the Run-in Period the patient must satisfy the following criteria based on the Screening laboratory values: * Estimated glomerular filtration rate (eGFR) ≥ 30 and ≤ 75 mL/min/1.73m2 by Epidemiology Collaboration (EPI) formula * Urinary Albumin to Creatinine Ratio (UACR) \> or = 300 and \< or = 3500 mg/g as determined by the geometric mean of the two morning void urine specimens obtained at the Screening visit (UACR \> or = 34 mg/mmol and \< or = 396 mg/mmol) * Serum albumin \> or = 3.0 g/dL (30 g/L) - B-type Natriuretic Peptide (BNP) \< or = 200 pg/mL (57.8 pmol/L) \* Negative serum pregnancy test for female patients * Systolic Blood Pressure (SBP) \> or = 110 mmHg and \< or = 180 mmHg * Glucosylated hemoglobin A1c (HbA1c) \< or = 12% * For entry in the Treatment Period the patient must satisfy the following criteria based on the last visit of the Run-in Period laboratory values: * Renin Angiotensin System (RAS) inhibitor at maximum tolerated labeled dose for the previous 4 weeks with no adjustments of dose * Diuretic at any dose unless medically contraindicated (with the exception of loop diuretics \> or = 120 mg QD of furosemide or \> or = 3.0 mg QD of bumetanide or \> or = 150 mg QD of ethacrynic acid or \> or = 60 mg QD of torasemide) * Urinary Albumin to Creatinine Ratio (UACR) \> or = 200 and \< or = 3500 mg/g as determined by the median of the three morning void urine specimens obtained prior to the Week -1 visit (UACR \> or = 23 mg/mmol and \< or = 396 mg/mmol) * Systolic blood pressure (SBP) \> or = 110 mmHg and \< or = 160 mmHg * Serum Potassium \< or = 5.5 mEq/L (5.5 mmol/L) * Negative serum pregnancy test for female patients Exclusion Criteria: * Patient has a history of moderate or severe edema, facial edema unrelated to trauma, or a history of myxedema in the prior 6 months to Screening. * Patient is receiving loop diuretics \> or = 120 mg QD of furosemide or \> or = 3.0 mg QD of bumetanide or \> or = 150 mg QD of ethacrynic acid or \> or = 60 mg QD of torasemide. * Patient has a history of pulmonary edema. * Patient has a history of pulmonary hypertension, or any lung diseases requiring oxygen therapy (i.e., chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis). * Patient has a history of orthostatic hypotension within the past 6 months as defined by the presence of a supine-to-standing blood pressure decrease \> or = 20 mmHg systolic or \> or = 10 mmHg diastolic within 3 minutes of standing.